Mani Mohindru, Ph.D.
Chief Financial Officer and Chief Strategy Officer
Dr. Mohindru joined the company in August, 2017 as our Chief Financial Officer and Chief Strategy Officer. She came to Cara Therapeutics from Curis, Inc. where she was most recently its Chief Strategy Officer. Previously, Dr. Mohindru has spent several years as a Wall Street research analyst covering the biotechnology industry at ThinkEquity, Credit Suisse and UBS, and in the investment banking division at Capstone Investments. She has also been a strategic consultant to the pharmaceutical and biotechnology industry at Axon Healthcare Partners and SAI Healthcare (acquired by IMS Health) and was a co-founder of ImmTox, Inc., an oncology-focused private biotechnology company.
Dr. Mohindru received her Ph.D. in Neurosciences from Northwestern University, and Masters in Biotechnology as well as B.Sc (Hons) Human Biology from the All India Institute of Medical Sciences, New Delhi, India.